摘要
目的通过检测乳腺癌患者血浆热休克蛋白90α(Hsp90α)水平,探讨其在乳腺癌临床诊疗中的应用价值。方法采用酶联免疫吸附试验(ELISA)检测289例乳腺癌患者、172例乳腺良性疾病患者及90名健康体检者(正常对照组)血浆Hsp90α水平,分析Hsp90α在患者不同病理因素(年龄、肿瘤大小、临床分期及有无淋巴结转移等)间的差异。结果乳腺癌组血浆Hsp90α水平明显高于乳腺良性疾病组和正常对照组(P<0.001)。不同年龄乳腺癌患者之间血浆Hsp90α水平差异无统计学意义(P>0.05),肿瘤≥3 cm、病理分期Ⅱ~Ⅳ期、有淋巴结转移者的血浆Hsp90α水平分别高于肿瘤<3 cm(P=0.003)、病理分期Ⅰ期(P<0.001)和无淋巴结转移者(P=0.031)。结论血浆Hsp90α是一个潜在的乳腺肿瘤标志物,对乳腺癌的辅助诊断和预后判断有一定作用。
Objective To investigate the role of plasma heat shock protein 90 alpha （Hsp90α） in the diagnosis and treatment of breast cancer. Methodse Plasma samples were collected from 289 patients with breast cancer,172 patients with benign breast disease and 90 healthy subjects （healthy control group）. Enzyme-linked immunosorbent assay（ELISA） was used for determining Hsp90α levels,and the difference of Hsp90α levels among age,tumor size,clinical stage and lymphatic metastasis was analyzed. Results The level of Hsp90α in breast cancer group was higher than those in benign breast disease and healthy control groups（P〈0.001）. There was no statistical significance for Hsp90α levels with different ages （P〉0.05）. Hsp90α levels in patients with a tumor≥3 cm,inⅡ-Ⅳclinical stages and with lymphatic metastasis were higher than those with a tumor 〈3 cm （P=0.003）,inⅠclinical stage （P〈0.001） and without lymphatic metastasis （P=0.031）,respectively. Conclusions Plasma Hsp90α might be a potential tumor marker for breast cancer,which plays a role in the diagnosis and prognosis of breast cancer.
出处
《检验医学》
CAS
2017年第5期374-377,共4页
Laboratory Medicine
